$3.87
5.38%
Nasdaq, Jan 02, 10:08 pm CET
Why the stock moved Why the stock moved Beta
ISIN
NL0015000DX5
Symbol
ATAI

ATAI Life Sciences N.V. Stock price

$3.87
+0.00 0.00% 1M
+1.12 40.73% 6M
-0.22 5.38% YTD
+2.27 141.88% 1Y
+1.21 45.49% 3Y
-15.58 80.10% 5Y
-15.58 80.10% 10Y
-15.58 80.10% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.22 5.38%
ISIN
NL0015000DX5
Symbol
ATAI
Industry

New AI Insights on ATAI Life Sciences N.V. Insights AI Insights on ATAI Life Sciences N.V.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$1.3b
Net debt
positive
Cash
$114.6m
Shares outstanding
240.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
465.4 | 437.5
EV/Sales
427.5 | 401.8
EV/FCF
negative
P/B
8.8
Financial Health
Equity Ratio
73.0%
Return on Equity
-128.4%
ROCE
-32.7%
ROIC
-61.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$3.0m | $3.2m
EBITDA
$-72.1m | $-106.4m
EBIT
$-73.0m | $-106.2m
Net Income
$-115.2m | $-155.0m
Free Cash Flow
$-90.3m
Growth (TTM | estimate)
Revenue
815.2% | 936.5%
EBITDA
32.4% | -7.1%
EBIT
31.7% | -6.5%
Net Income
10.4% | -3.9%
Free Cash Flow
-12.7%
Margin (TTM | estimate)
Gross
-
EBITDA
-2,384.3% | -3,311.1%
EBIT
-2,414.1%
Net
-3,811.9% | -4,824.9%
Free Cash Flow
-2,988.4%
More
EPS
$-0.5
FCF per Share
$-0.4
Short interest
4.8%
Employees
54
Rev per Employee
$10.0k
Show more

Is ATAI Life Sciences N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

ATAI Life Sciences N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a ATAI Life Sciences N.V. forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a ATAI Life Sciences N.V. forecast:

Buy
94%
Hold
6%

Financial data from ATAI Life Sciences N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
3.02 3.02
815% 815%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 40 40
26% 26%
1,313%
- Research and Development Expense 36 36
28% 28%
1,203%
-72 -72
32% 32%
-2,387%
- Depreciation and Amortization 0.90 0.90
157% 157%
30%
EBIT (Operating Income) EBIT -73 -73
32% 32%
-2,417%
Net Profit -115 -115
10% 10%
-3,816%

In millions USD.

Don't miss a Thing! We will send you all news about ATAI Life Sciences N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ATAI Life Sciences N.V. Stock News

Neutral
Proactive Investors
4 days ago
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has completed the redomiciliation of its parent company from the Netherlands to the United States, with the new entity incorporated in Delaware. The move was approved by approximately 99% of the votes cast at the company's extraordinary general meeting of shareholders held on November 4.
Positive
Proactive Investors
12 days ago
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that its common stock has been added to the Nasdaq Biotechnology Index (NBI), effective prior to the market open on December 22. The NBI is designed to track the performance of biotechnology and pharmaceutical companies listed on the Nasdaq Stock Market that meet specific eligibility criteria, including minimum market capitalization, average dai...
Neutral
GlobeNewsWire
12 days ago
NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced its common stock has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prio...
More ATAI Life Sciences N.V. News

Company Profile

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

Head office Netherlands
CEO Dr. Rao
Employees 54
Founded 2018
Website www.atai.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today